News Releases June 14, 2023 Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor Read more June 7, 2023 Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis Read more May 31, 2023 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more May 11, 2023 Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress Read more May 4, 2023 Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 Read more March 24, 2023 Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Read more March 23, 2023 Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress Read more March 15, 2023 Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023 Read more March 11, 2023 Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure Read more February 28, 2023 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences Read more First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 31 - 40 of 66
